A share price of CorMedix Inc [CRMD] is currently trading at $11.18, up 5.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRMD shares have gain 11.19% over the last week, with a monthly amount drifted -8.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CorMedix Inc [NASDAQ: CRMD] stock has seen the most recent analyst activity on January 13, 2025, when D. Boral Capital initiated its Buy rating and assigned the stock a price target of $15. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 26, 2024, and set its price target to $13. On August 10, 2023, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $6 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $31 on February 17, 2021. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $22 as its price target on September 29, 2020. Truist started tracking with a Buy rating for this stock on September 21, 2020, and assigned it a price target of $20. In a note dated December 18, 2019, B. Riley FBR initiated an Buy rating and provided a target price of $48 on this stock.
CorMedix Inc experienced fluctuations in its stock price throughout the past year between $3.03 and $13.85. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. CorMedix Inc [NASDAQ: CRMD] shares were valued at $11.18 at the most recent close of the market. An investor can expect a potential drop of -19.5% based on the average CRMD price forecast.
Analyzing the CRMD fundamentals
Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -4.06%, Pretax Profit Margin comes in at -3.78%, and Net Profit Margin reading is -3.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.79 and Total Capital is -0.86. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.70 points at the first support level, and at 10.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.47, and for the 2nd resistance point, it is at 11.76.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CorMedix Inc [NASDAQ:CRMD] is 3.96. In addition, the Quick Ratio stands at 3.60 and the Cash Ratio stands at 1.91. Considering the valuation of this stock, the price to sales ratio is 55.31, the price to book ratio is 11.02.
Transactions by insiders
Recent insider trading involved Mistry Erin, EVP, Chief Commercial Officer, that happened on Oct 31 ’24 when 1500.0 shares were purchased. EVP, Hurlburt Elizabeth completed a deal on Nov 14 ’24 to sell 0.14 million shares. Meanwhile, Officer Hurlburt Elizabeth bought 0.14 million shares on Nov 14 ’24.
